Administration of mGlu2/3R agonist in a model of chronic cerebral hypoperfusion

J. TURATI; A. NUNES SANTIAGO; L. CARNIGLIA; J. SABA; C. CARUSO; D. DURAND; R. WEFFORT DE OLIVEIRA; M. LASAGA

Mar del Plata

Congreso; SAIC; 2019

Chronic cerebral hypoperfusion (CCH) resembles central changes in aging-related vascular dementias and Alzheimer´s disease (AD). Our group has demonstrated, in vitro, that astroglial subtype 3 metabotropic glutamate receptors (mGlu3R) present protective actions against neurotoxic agents including A. However, contradictory results were reported when mGlu3R ligands were administered in vivoWe examined the effect of the mGlu2/3R agonist, LY376298 (LY) 1mg/kg i.p., in middle aged rats with CCH. The effect of mGlu2/3R agonist in neuron cell death and glial activation of the hippocampus were determined by immunohistochemistry. Moreover, the expression of GRM2, GRM3 (mGlu2/3R genes), GFAP and BDNF was studied by RT-qPCR technique.NeuN expression presents a decreased in CCH animals (p